SQZ stock gains as H.C. Wainwright starts with Buy citing platform technology (NYSE:SQZ)
seekingalpha.com
news
2022-10-20 13:24:16

naphtalina/iStock via Getty Images SQZ Biotechnologies (NYSE:SQZ), a biotech focused on cell therapies, added ~5% pre-market Thursday after H.C. Wainwright launched its coverage with a Buy rating and a $5 target highlighting the company's Cell Squeeze technology platform. The analyst Emily Bodnar notes that the Cell Squeeze technology is designed to address many shortcomings in current cell therapy platforms as it doesn't require lymphodepletion, allows flexibility of cell type and cargo, and faster production while maintaining cell health and function.
